MAP2K7 and cancer: As in other kinases, mutation of this residue causes inactivation and thus cancer mutants such as D594VBRAF cannot phosphorylate MEK, activate CRAF, or stimulate cell signaling (Ikenoue et al., 2003; Wan et al., 2004).